Letter to the editor

 

Sexually transmitted infections in women with fertility problems in aragua, venezuela

 

César Pacheco 1, Biologist, Master in Biochemistry and Molecular Biology
Jham Lugo 2, Obstetrician-Gynecologist, Master in Reproductive Medicine
Narviz Pulido 1, Bioanalyst, Master in Biochemistry and Molecular Biology
Heriberto Correia 1, Bioanalyst, Doctor in Cellular Biology
Nancy Moreno 1, Biologist, Doctor in Molecular Biology
Flor Herrera 1, Chemist, Doctor in Biochemistry

1 Instituto de Investigaciones Biomédicas (BIOMED) "Dr. Francisco J. Triana Alonso", Facultad de Ciencias de la Salud, Núcleo Aragua, Universidad de Carabobo, Venezuela.

 


To the editor. Some sexually transmitted infections (STIs) can cause infertility in women (1). In Venezuela there are few published reports on the proportion of these infections in women with fertility problems; therefore, there is a need to increase knowledge on this subject. The aim of this study was to determine the proportion of STIs due to C. trachomatis, T. vaginalis, N. gonorrhoeae, andMycoplasmas (M. hominis, M.genitalium and U. urealyticum) in a group of women with fertility problems who attended the Fertility Center (CenFer) located in the city of Maracay, Aragua state during the years 2016-2019.

We conducted a cross-sectional study, with a continuous selection sample and non-probabilistic sampling. Infertility was defined according to the World Health Organization (WHO) (2). Heterosexual women who were sexually active, of reproductive age with primary or secondary infertility, nulliparous, with previous children or with history of previous or anembryonic abortions were included. Women on antibiotic treatment seven days prior to sampling were excluded.

The cervical swab sample was transferred from CenFer to the Biomedical Research Institute (BIOMED) for molecular diagnosis. DNA from the swabs was extracted with the phenol-chloroform method, its integrity was determined by electrophoresis in 1% agarose gels and its concentration by absorbance at 260 nm. DNA amplification was carried out using the method described by the manufacturer of the commercial Seeplex® STD6 ACE detection kit (Seegene, Seoul, Korea). This kit contains six specific primer pairs to detect single genes of the pathogens C. trachomatis, T. vaginalis, N. gonorrhoeae, M. hominis, M. genitalium and U. urealyticum; positive DNA controls are included. Amplification products were visualized by electrophoresis on 2% agarose gels. The sample was considered positive if it had one pathogen, negative if it had none, and mixed if it had two or more pathogens.

Absolute and relative frequency distributions were calculated for the results of the species identification tests and the chi-square (χ2) homogeneity test was used to compare the proportion of each of the infections between the studied years. Data were processed with RStudio 1.1.463 statistical software.

The average age was 33.6 ± 7.8 years with a range of 18 to 50 years. Table 1 shows the percentages of positive, mixed and negative samples, and the frequency distribution of pathogens in the most mixed positive samples, during the 2016-2019 period. The χ2 homogeneity test showed that the annual proportions of positive and negative samples, as well as the species identified, were not homogeneous for the studied period (χ2=35.96; p<0.001 and χ2= 33.36; p=0.003, respectively).

 

Table 1. Proportion and distribution of pathogens detected in women with fertility problems during 2016-2019. 

 

2016 n=125 (%)

2017 n=144 (%)

2018 n=101 (%)

2019 n=123 (%)

Total N=493 (%)

p-value a

Sample

 

 

 

 

 

 

Positive

80

(64.0)

86

(59.7)

35

(34.7)

55

(44.7)

256
(51.9)

 

Mixed

12

(9.6)

20

(13.9)

9
(8.9)

8
(6.5)

49

(9.9)

<0.001

Negative

33

(26.4)

38

(26.4)

57

(56.4)

60

(48.8)

188
(38.2)

 

Pathogens in the most mixed positive samples

 

 

 

 

 

 

M. hominis

29

(23.2)

32

(22.2)

19

(18.9)

33

(26.8)

113
(22.9)

0.034

U. urealyticum

32

(25.6)

39

(27.1)

10

(9.9)

5
(4.1)

86

(17.4)

0.001

C. trachomatis

18

(14.4)

15

(10.4)

6
(5.9)

16

(13.0)

55

(11.2)

0.392

N. gonorrhoae

6
(4.8)

9
(6.3)

1
(0.9)

3
(2.4)

19

(3.9)

0.676

T. vaginalis

4
(3.2)

7
(4.9)

3
(2.9)

5
(4.1)

19

(3.9)

0.922

M. genitalium

3
(2.4)

4
(2.7)

5
(4.9)

1
(0.8)

13

(2.6)

0.138

a Chi-square test for homogeneity.

 

The percentage of positive samples was high in 2016 (64.0%) and 2017 (59.7%) and decreased in 2018 (34.7%) and 2019 (44.7%). There was a shortage of health supplies during 2016-2017, and during 2018-2019 the import of these supplies increased (3). Quite possibly, our results were influenced by sociopolitical-economic factors that occurred in Venezuela during the 2016-2019 period (3). Retrospective studies are needed to corroborate these findings.

The percentage of C. trachomatis was 11.2%, similar to that found in a study performed in infertile women (11.5%) (4), which suggests a participation of this pathogen in the infertility of some patients.

The percentages of N. gonorrhoeae, M. genitallum, and T. vaginalis were lower than those found in other studies on infertile women. Literature reports conflicting results for U. urealyticum and M. hominis. A study on infertile women found that the percentage of U. urealyticum and M. hominis was 51.7% and 26.7%, respectively (5). Another study in infertile and fertile women reported low percentages: U. urealyticum (6.6% infertile and 2.5% fertile) and M. hominis (5.3% infertile and 1.5% fertile) (6). Our study found percentages of 17.4% for U. urealyticum and 22.9% for M. hominis, these values more closely resembling the group of infertile women. In addition, these last two pathogens were the only ones that had a statistically significant annual variation, U. urealyticum decreased over time while M. hominis increased. It would be important to determine the cause of this behavior.

A limitation of our study is that the sample consisted only of women with fertility problems, so the data cannot be generalized to the entire population of Venezuelan women.

Finally, positive samples for STIs were higher in the first two years of the 2016-2019 period. This could have multiple causes such as a major shortage of drugs due to the sociopolitical-economic crisis in the country (3), the increase in the number of sexual partners or the lack of interest in timely and preventive urogynecological consultation. Of all these possibilities, it can only be confirmed that during the years 2016-2017 there was an 80% shortage of health supplies (3) and this could have influenced the increase in STIs.

Acknowledgments: The authors thank magister Luis Pérez- Ybarra for his collaboration in the statistical analysis of the results, biologist Isolina Marval and magister Adriana Fernández for elaborating the patient database; graduate Teresa Oropeza for her participation in some trials and all the patients for giving their consent for the realization of this study.

Author contributions: JL designed and executed the clinical gynecologic study and obtained the gynecologic samples; CP and NP carried out the molecular assays for STI detection; HC, NM and FH designed and conducted the molecular study of STIs; and FH was in charge of writing the manuscript with the help of NM and CP. All authors discussed and analyzed the results and contributed to the final manuscript.

Conflicts of interest: None.

Ethical criteria: Patients signed an informed consent form, approved by the Bioethics Committee of the Institute of Biomedical Research (BIOMED) of the University of Carabobo in 2015 with continuous revisions.

Funding: The BIOMED Diagnostic Laboratory of the University of Carabobo provided the materials and reagents for molecular diagnosis and CenFer provided the material for sample collection.

 

REFERENCES

1. World Health Organization. Global health sector strategy on sexually transmitted infections 2016–2021. Towards ending STIs [internet]. 1erst ed. Geneva: WHO; 2016. [cited 2022 Jan 9]. Available from: https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/.

2. World Health Organization. Infertility. Geneva: WHO; 2021. [cited 2022 Jan 9]. Available from: https://www.who.int/health-topics/infertility#tab=tab_1.

3. Carrillo A. Sistema de salud en Venezuela: ¿un paciente sin remedio? Cad Saúde Pública. 2018; 34 (3). doi: 10.1590/0102-311X00058517.

 4. Dhawan B, Rawre J, Ghosh A, Malhotra N, Ahmed MM, Sreenivas V, et al. Diagnostic efficacy of a real time-PCR assay for Chlamydia trachomatis infection in infertile women in north India. Indian J Med Res. 2014;140(2):252-61.

5. Peerayeh SN, Sattari M. Detection of Ureaplasma urealyticum and Mycoplasma hominis in endocervical specimens from infertile women by polymerase chain reaction. Middle East Ft Soc J. 2006;11(2):104-108

6. Seifoleslami M, Safari A, Khayyat Khameneie M. Prevalence of Ureaplasma urealyticum and Mycoplasma hominis in High Vaginal Swab Samples of In- fertile Females. Iran Red Crescent Med J. 2015; 17(12): e16823. doi: 10.5812/ircmj.16823.

 

Cite as: Pacheco C, Lugo J, Pulido N, Correia H, Moreno N, Herrera F. Sexually transmitted infections in women with fertility problems in Aragua, Venezuela. Rev Peru Med Exp Salud Publica. 2022;39(2). doi: https://doi.org/10.17843/rpmesp.2022.392.10889.

Correspondence: Flor Herrera; flormhq@gmail.com

Received: 25/02/2022
Approved: 04/05/2022
Online: 20/06/2022